A phase II study to assess the efficacy and safety of frontline combination of dasatinib (SPRYCEL�) and pegylated-interferon alpha 2b (Peg-IFN?2b) therapy in patients newly diagnosed with chronic phase chronic myeloid leukaemia (CP-CML)
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest